Summary:
An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder
Qualified Participants Must:
Males or females at least 18 years of age
Qualified Participants May Receive:
Compensation for time and travel. Study medication will be provided.